Production Center

The Xianshi Pharmaceutical Production Center currently has about 300 employees, with 20% of them holding intermediate or senior professional titles. We have established 17 production lines in 8 formulation workshops, including oral solid preparations (tablets, granules, hard capsules, soft capsules), topical semi-solid preparations, oral liquid preparations, small volume sterile preparations (oil injections, water injections), large volume injections, small volume BFS for glucocorticoids, progesterone pre encapsulation, and Class III medical devices, as well as 4 raw material workshops. We have achieved full chain production capacity from raw materials to formulations and can undertake commissioned processing business (CMO) for raw materials and formulations.

Oral solid preparation workshop

▹ Tablets, capsules, granules, soft capsules, etc ▹ Annual production capacity: 1 billion tablets, approximately 500 million capsules, 50 million bags (or bottles) of granules, and 100 million soft capsules

Oral solution workshop

▹ Single dose oral liquid, multi dose oral liquid, composite film strip packaged single dose oral liquid ▹ Annual production capacity: 42 million bottles of 10ml oral solution, 12 million bottles of 50ml oral solution, and 46.8 million bags of bagged oral solution

Large infusion workshop

▹ Non PVC soft bag infusion solution ▹ Annual production capacity: 34.8 million bags

API Workshop

▹ Multi functional workshop that can meet the needs of most raw material drug synthesis processes ▹ Annual production capacity: Raw material workshop 1 has an annual production capacity of 100 tons, raw material workshop 2 has an annual production capacity of 60 tons, and raw material workshop 3 has an annual production capacity of 40 tons

Pre charging needle workshop 1

▹ Pre filled needle injection ▹ Annual production capacity: 13.5 million progesterone pre filled needles

External preparation workshop 1

▹ Cream, ointment, gel ▹ Annual production capacity: 3.5 million units

Integrated Formulation Workshop 1

▹ Small volume injectables (non final sterilization, final sterilization), inhalation preparations, ophthalmic preparations ▹ Annual production capacity (final and non final sterilization): 54 million units of 1-2ml injections, 48 million units of 5ml injections, 36 million units of 10ml injections, 24 million units of 20ml injections, and 36 million units of inhaled and ophthalmic preparations

Medical Device Workshop

▹ Pre filled needles for Class III medical devices ▹ Annual production capacity: 13.5 million units

R&D Center

Xianshi Pharmaceutical R&D Center has established six major R&D platforms, with over 100 R&D personnel and a master's and doctoral degree ratio of over 30%; There are over 90 ongoing research projects covering innovative drugs, high-end generic formulations, and raw materials, covering fields such as antiviral, anti infective, cardiovascular and cerebrovascular, endocrine, oncology, metabolism, and immunology.

Raw material development platform

▹ Development and industrialization platform for active pharmaceutical ingredients and excipients. ▹ Focusing on the synthesis of complex compounds, industrial transformation, and green chemistry technology, providing efficient and environmentally friendly raw material solutions.

New drug development platform

▹ Core platform for innovative drug design and product development in categories 1 and 2. ▹ Focusing on the discovery of new drug targets, exploring cutting-edge therapies, and promoting breakthroughs in innovative drugs from research and development to clinical practice.

Formulation development platform

▹ Development platform for chemical generic drugs and new drug formulations. ▹ Overcome the technical difficulties of high difficulty formulations and develop more patient compliant, safer, and more effective formulation products.

Quality Research Platform

▹ Drug quality research and full process quality control support platform. ▹ Collaborate with various process departments to develop new variety analysis methods and establish quality standards, ensuring stable and reliable drug quality throughout the entire process.

Clinical Medicine Platform

▹ Professional management platform for drug clinical research. ▹ Responsible for the evaluation, development, and full cycle management of clinical protocols for Class 3 and Class 4 generic drugs and innovative drugs, ensuring compliance and efficiency in clinical research.

Project management and registration platform

▹ Integrated platform for full process control and registration application of ongoing projects. ▹ Responsible for project progress and quality supervision, R&D data inspection and declaration material review, ensuring project quality and registration compliance. ▹ Coordinate the writing of project application materials and registration application work, and promote the smooth acquisition of registration approvals for the project.